{
    "nct_id": "NCT04629508",
    "official_title": "A 2-Part, Phase 2, Open-Label Study of the Safety, Tolerability, and Efficacy of Itacitinib Immediate Release in Participants With Primary Myelofibrosis or Secondary Myelofibrosis (Post-Polycythemia Vera Myelofibrosis or Post-Essential Thrombocythemia Myelofibrosis) Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy",
    "inclusion_criteria": "* Diagnosis of primary MF meeting the 2016 WHO criteria for overt PMF or secondary MF (PPV-MF or PET-MF) meeting the 2008 IWG-MRT criteria.\n* At least Intermediate 1 risk MF according to the DIPSS.\n* Prior treatment with ruxolitinib and/or fedratinib monotherapy\n* Currently receiving ruxolitinib or fedratinib monotherapy for PMF or secondary MF.\n* Splenomegaly defined as palpable spleen at least 5 cm below the left costal margin or volume ≥ 450 cm3 on imaging assessed during screening.\n* Allogeneic stem cell transplant not planned.\n* Platelet is greater than or equal to 50 × 109/L at screening.\n* Ability to comprehend and willingness to sign a written ICF for the study.\n* Willingness to avoid pregnancy or fathering children.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Prior treatment with a JAK inhibitor other than ruxolitinib or fedratinib\n* Record of ≥ 10% myeloid blasts in the peripheral blood (on peripheral blood smear) or bone marrow prior to or at the time of screening\n* For participants on ruxolitinib or fedratinib, unable to be tapered from that treatment over the course of 14 days without corticosteroids, hydroxyurea, or other agents\n* Treatment with ruxolitinib, fedratinib or other MF-directed therapy (approved or investigational) within 2 weeks of Day 1\n* Prior splenectomy or splenic irradiation within 6 months before receiving the first dose of itacitinib\n* Unable or unwilling to undergo serial MRI or CT scans for spleen volume measurement\n* Unable or unwilling to complete MFSAF v4.0 diary on a daily basis during the study\n* ECOG performance status ≥ 3\n* Life expectancy less than 24 weeks\n* Not willing to receive RBC or platelet transfusions\n* Participants with laboratory values at screening outside of protocol defined ranges\n* Significant concurrent, uncontrolled medical condition\n* Participants with impaired cardiac function or clinically significant cardiac disease unless approved by medical monitor/sponsor\n* History or presence of an abnormal ECG that, in the investigator's opinion, is clinically meaningful\n* Chronic or current active infectious disease requiring systemic antibiotics, antifungal, or antiviral treatment.\n* Evidence of HBV or HCV infection or risk of reactivation\n* Known HIV infection.",
    "miscellaneous_criteria": ""
}